R-7050 | CAS#303997-35-5 | TNF-α receptor antagonist

R-7050
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562551

CAS#: 303997-35-5

Description: R-7050 is a TNF-α receptor antagonist. It acts by blocking receptor-adaptor molecule complex formation and subsequent receptor internalization, but not TNF-α ligand-receptor binding.

Chemical Structure

R-7050

CAS# 303997-35-5

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 562551
Name: R-7050
CAS#: 303997-35-5
Chemical Formula: C16H8ClF3N4S
Exact Mass: 380.01
Molecular Weight: 380.770
Elemental Analysis: C, 50.47; H, 2.12; Cl, 9.31; F, 14.97; N, 14.71; S, 8.42

Price and Availability

Size	Price	Availability
1mg	USD 180	2 weeks
5mg	USD 330	2 weeks
10mg	USD 580	2 weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: R-7050; R 7050; R7050; TNF-α Antagonist III;

IUPAC/Chemical Name: 8-Chloro-4-(phenylthio)-1-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]quinoxaline

InChi Key: SUUMKHOVGVYGOP-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H8ClF3N4S/c17-9-6-7-11-12(8-9)24-13(22-23-15(24)16(18,19)20)14(21-11)25-10-4-2-1-3-5-10/h1-8H

SMILES Code: FC(C1=NN=C2N1C3=C(C=CC(Cl)=C3)N=C2SC4=CC=CC=C4)(F)F

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO (need ultrasonic)

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	R-7050 acts by blocking receptor-adaptor molecule complex formation and subsequent receptor internalization, but not TNF-α ligand-receptor binding.
In vitro activity:	To be determined
In vivo activity:	This study found that repetitive injection of Taraxaci Herba and/or R-7050 reduced the symptoms of Behçet's disease and significantly decreased IL-6, IL-1β, and TNFα in blood sera of mice. This treatment reduced the ulcers and the deterioration of skin. Reference: Integr Med Res. 2021 Sep;10(3):100720. https://pubmed.ncbi.nlm.nih.gov/33898245/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO (need ultrasonic)	25.0	65.66

Preparing Stock Solutions

The following data is based on the product molecular weight 380.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Cha M, Kwon M, Park M, Oh JH, Sung KK, Lee BH. Combined treatment of Taraxaci Herba and R7050 alleviates the symptoms of herpes simplex virus-induced Behçet's disease in rats. Integr Med Res. 2021 Sep;10(3):100720. doi: 10.1016/j.imr.2021.100720. Epub 2021 Feb 17. PMID: 33898245; PMCID: PMC8059053. 2. Wen Y, Lu X, Ren J, Privratsky JR, Yang B, Rudemiller NP, Zhang J, Griffiths R, Jain MK, Nedospasov SA, Liu BC, Crowley SD. KLF4 in Macrophages Attenuates TNFα-Mediated Kidney Injury and Fibrosis. J Am Soc Nephrol. 2019 Oct;30(10):1925-1938. doi: 10.1681/ASN.2019020111. Epub 2019 Jul 23. PMID: 31337692; PMCID: PMC6779357.
In vitro protocol:	To be determined
In vivo protocol:	1. Cha M, Kwon M, Park M, Oh JH, Sung KK, Lee BH. Combined treatment of Taraxaci Herba and R7050 alleviates the symptoms of herpes simplex virus-induced Behçet's disease in rats. Integr Med Res. 2021 Sep;10(3):100720. doi: 10.1016/j.imr.2021.100720. Epub 2021 Feb 17. PMID: 33898245; PMCID: PMC8059053. 2. Wen Y, Lu X, Ren J, Privratsky JR, Yang B, Rudemiller NP, Zhang J, Griffiths R, Jain MK, Nedospasov SA, Liu BC, Crowley SD. KLF4 in Macrophages Attenuates TNFα-Mediated Kidney Injury and Fibrosis. J Am Soc Nephrol. 2019 Oct;30(10):1925-1938. doi: 10.1681/ASN.2019020111. Epub 2019 Jul 23. PMID: 31337692; PMCID: PMC6779357.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Mulay SR, Eberhard JN, Desai J, Marschner JA, Kumar SV, Weidenbusch M, Grigorescu M, Lech M, Eltrich N, Müller L, Hans W, Hrabě de Angelis M, Vielhauer V, Hoppe B, Asplin J, Burzlaff N, Herrmann M, Evan A, Anders HJ. Hyperoxaluria Requires TNF Receptors to Initiate Crystal Adhesion and Kidney Stone Disease. J Am Soc Nephrol. 2017 Mar;28(3):761-768. doi: 10.1681/ASN.2016040486. Epub 2016 Sep 9. PubMed PMID: 27612997; PubMed Central PMCID: PMC5328164.

2: Yang N, Liang Y, Yang P, Wang W, Zhang X, Wang J. TNF-α receptor antagonist attenuates isoflurane-induced cognitive impairment in aged rats. Exp Ther Med. 2016 Jul;12(1):463-468. Epub 2016 Apr 18. PubMed PMID: 27347079; PubMed Central PMCID: PMC4906939.

3: Ma Y, Cheng Q, Wang E, Li L, Zhang X. Inhibiting tumor necrosis factor-α signaling attenuates postoperative cognitive dysfunction in aged rats. Mol Med Rep. 2015 Aug;12(2):3095-100. doi: 10.3892/mmr.2015.3744. Epub 2015 May 7. PubMed PMID: 25955232.

4: Wu W, Zhang H. Role of tumor necrosis factor-α and interleukin-1β in anorexia induction following oral exposure to the trichothecene deoxynivalenol (vomitoxin) in the mouse. J Toxicol Sci. 2014;39(6):875-86. PubMed PMID: 25392278.

5: King MD, Alleyne CH Jr, Dhandapani KM. TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice. Neurosci Lett. 2013 May 10;542:92-6. doi: 10.1016/j.neulet.2013.02.051. Epub 2013 Mar 7. PubMed PMID: 23499961; PubMed Central PMCID: PMC3744337.

Your view history

R-7050 featured